MD

Matthew During

OT Ovid Therapeutics: 50 patents #1 of 3Top 35%
NE Neurologix: 6 patents #1 of 8Top 15%
TU Thomas Jefferson University: 4 patents #66 of 538Top 15%
TU The Rockefeller University: 3 patents #136 of 698Top 20%
YU Yale University: 2 patents #418 of 1,662Top 30%
MIT: 1 patents #4,386 of 9,367Top 50%
ME Medtronic: 1 patents #4,185 of 6,325Top 70%
OU Ohio State University: 1 patents #193 of 584Top 35%
OU Oxford University: 1 patents #234 of 681Top 35%
The General Hospital: 1 patents #1,411 of 3,021Top 50%
UN Unknown: 1 patents #29,356 of 83,584Top 40%
📍 Darien, CT: #4 of 243 inventorsTop 2%
🗺 Connecticut: #252 of 34,797 inventorsTop 1%
Overall (All Time): #29,932 of 4,157,543Top 1%
69
Patents All Time

Issued Patents All Time

Showing 1–25 of 69 patents

Patent #TitleCo-InventorsDate
12285397 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders Brett Abrahams 2025-04-29
12144801 Methods and compositions for treatment of epileptic disorders 2024-11-19
12109201 Methods and compositions for treatment of epileptic disorders 2024-10-08
11918563 Methods and compositions for treatment of epileptic disorders 2024-03-05
11918551 Methods of treating seizure disorders and Prader-Willi syndrome 2024-03-05
11903930 Methods and compositions for treatment of epileptic disorders 2024-02-20
11806336 Methods and compositions for treatment of epileptic disorders 2023-11-07
11771671 Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction 2023-10-03
11761006 Use of MIR101 or MIR128 in the treatment of seizure disorders 2023-09-19
11690829 Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder 2023-07-04
11660277 Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders Brett Abrahams 2023-05-30
11395817 Methods and compositions for treatment of epileptic disorders 2022-07-26
11364228 Gaboxadol for therapeutic treatment of 1p36 deletion syndrome 2022-06-21
11291658 Use of gaboxadol in the treatment of diabetes and related conditions 2022-04-05
11278529 Methods for treating aggression associated with Alzheimer's disease 2022-03-22
11130952 Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome 2021-09-28
11096929 Methods of treating developmental disorders with gaboxadol 2021-08-24
11090293 Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering 2021-08-17
10925879 Methods of treating developmental disorders and/or seizure disorders with etifoxine 2021-02-23
10870855 Use of MIR101 or MIR128 in the treatment of seizure disorders 2020-12-22
10813899 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders Brett Abrahams 2020-10-27
10813918 Use of Gaboxadol in the treatment of diabetes and related conditions 2020-10-27
10799485 Methods and compositions for treatment of epileptic disorders 2020-10-13
10765666 Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering 2020-09-08
10765646 Methods of treating developmental encephalopathies 2020-09-08